JPRN-UMIN000026315已完成4 期
SGLT2 Inhibition in Patients With Type 2 Diabetes Mellitus and Acute Decompensated Heart Failure: SLIM-AHF Study - SLIM-AHF
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 250
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Patients with severe primary valvular heart disease 2) Patients with acute coronary syndrome 3) Patients with heart transplantation 4) Patients who do not need diuretic therapy because of dehydration 5) Patients with cardiogenic shock at eligibility qualification 6) Patients with intubation and mechanical ventilation at eligibility qualification 7) Patients who need mechanical circulatory assist device (IABP, PCPS) at eligibility qualification 8) Patients with myocarditis 9) Patients with hypertrophic obstructive cardiomyopathy 10) Patients with type 1 diabetes mellitus 11) Patients with reduced endogenous insulin secretion (fasting C-peptide level <1.0 ng/mL) 12) Patients who had already been on SGLT2 inhibitors 13) Patients with severe diabetic ketoacidosis or diabetic coma 14) Patients with a history of hypersensitivity reaction to empagliflozin 15) Patients who cannot have diet or receive enteral nutrition therapy within 96 hours of admission 16) Patients who are pre or post surgery, or patients with severe infection or serious trauma 17) Patients whose life expectancy is less than 6 months due to extracardiac disease 18) Patients with severe renal dysfunction (estimated glomerular filtration rate <15mL/min/1.73m2) or those with dialysis 19) Patients with a history of acute coronary syndrome, stroke or transient ischemic attack within one month of eligibility qualification 20) Pregnant, possibly pregnant or lactating women 21) Patients who were judged inappropriate by the principal investigator
研究者
相似试验
招募中
不适用
Effects of a SGLT2 Inhibitor in type 2 Diabetes Mellitustype 2 Diabetes MellitusJPRN-UMIN000017461ephrology, endocrinology and vascular medicine at Tohoku University Hospital60
招募中
2 期
SGLT2 lnhibition in Hemodialysis (DAPA-HD)Chronic Kidney Disease2024-518591-31-00Medical University Of Vienna220
招募中
4 期
Effects of SGLT-2 inhibitors for the patients with non-alcoholic fatty liver disease (NAFLD) complicated with type 2 diabetes mellitus.on-alcoholic fatty liver disease (NAFLD) complicated with type 2 diabetes mellitus.JPRN-UMIN000018913Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine50
进行中（未招募）
1 期
The effects of SGLT2-inhibition in patients with type 2 diabetes and preserved kidney function on renal circulation, kidney function and hormones related to the circulatioType 2 diabetesMedDRA version: 21.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861EUCTR2019-004303-12-DKniversity Clinic of Nephrology and Hypertension, Regional Hospital Holstebro20
招募中
不适用
Efficacy and safety in SGLT2 inhibitor for diabetes complicated by non-alcoholic fatty liver disease.Type 2 diabetes complicated by non-alcoholic fatty liver diseaseJPRN-UMIN000018166Toranomon Hospital, Department of Hepatology15